evaluate novo nordisk on glp-1 agonists Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say Glucagon-like Peptide-1 (GLP-1) Agonists Market
Description
For heart failure per se, GLP-1 RAs have a neutral effect on HF hospitalizations (unlike SGLT2 inhibitors which specifically help HF)
-agonists-market-key-insight.png)
Wyse was named to King Charles IIIs New Year Honours List for 2024
In the spring of 2022, the Food and Drug Administration (FDA) approved tirzepatide for the management and treatment of T2DM, and it has also recently been approved in Europe
Titration schedules are generally planned to minimize early GI side effects
Annu Rev Med
GLP-1s may also be an option if youre unable to tolerate metformin due to side effects
